A screen of ADRs with IBD Composite Ratings of 80 or higher yielded 37 stocks Friday, but only a handful are potentially actionable. Generic-drug makers like Israel-based Teva Pharmaceutical Industries (TEVA) and India-based Dr. Reddy’s Laboratories (RDY) are setting up for possible breakouts, but both firms show inconsistent earnings and sales growth in recent quarters.